1. Scrip
  2. >>R&D

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

 
• By Joseph Haas

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

Loser concept. Hand drawn failure in business. Unfortunate attempt to hit the target isolated vector illustration.

Clinical development failures in major depressive disorder (MDD) are nothing new, but Allergan PLC’s trio of unsuccessful Phase III studies with NMDA receptor modulator rapastinel might be more damaging because of the company’s recent litany of R&D setbacks, along with Johnson & Johnson’s US approval in the same class with Spravato on March 5.

Allergan announced top-line results late in the day March 6 showing that rapastinel – a driver of its $560m purchase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.